These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 455327)

  • 1. Pharmacokinetic, toxicologic, and chemotherapeutic properties of detorubicin in mice: a comparative study with daunorubicin and adriamycin.
    Deprez-de Campeneere D; Baurain R; Trouet A
    Cancer Treat Rep; 1979 May; 63(5):861-7. PubMed ID: 455327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative study in mice of the toxicity, pharmacology, and therapeutic activity of daunorubicin-DNA and doxorubicin-DNA complexes.
    Deprez-De Campeneere D; Baurain R; Huybrechts M; Trouet A
    Cancer Chemother Pharmacol; 1979; 2(1):25-30. PubMed ID: 498415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cellular pharmacology of detorubicin and doxorubicin in L1210 cells.
    Zenebergh A; Baurain R; Trouet A
    Eur J Cancer Clin Oncol; 1984 Jan; 20(1):115-21. PubMed ID: 6537910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adriamycin and daunorubicin: a comparison of antitumor activities and tissue uptake in mice following immunosuppression.
    Schwartz HS; Grindey GB
    Cancer Res; 1973 Aug; 33(8):1837-44. PubMed ID: 4720795
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmacological and therapeutic efficacy of rubidazone in mice. Comparison with daunomycin and adriamycin.
    Ohnuma T; Elias F; Holland JF; Henderson E
    Eur J Cancer (1965); 1979 Mar; 15(3):363-71. PubMed ID: 446517
    [No Abstract]   [Full Text] [Related]  

  • 6. Enhancement of the effectiveness of daunorubicin (NSC-82151) or adriamycin (NSC-123127) against early mouse L1210 leukemia with ICRF-159 (NSC-129943).
    Woodman RJ; Cysyk RL; Kline I; Gang M; Venditti JM
    Cancer Chemother Rep; 1975; 59(4):689-95. PubMed ID: 1175163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA--anthracycline complexes. I. Toxicity in mice and chemotherapeutic activity against L1210 leukemia of daunorubicin--DNA and adriamycin--DNA.
    Deprez-de Campeneere D; Trouet A
    Eur J Cancer (1965); 1980 Aug; 16(8):981-6. PubMed ID: 7439227
    [No Abstract]   [Full Text] [Related]  

  • 8. Uptake of adriamycin and daunomycin in L1210 and human leukemia cells: a comparative study.
    Chervinsky DS; Wang JJ
    J Med; 1976; 7(1):63-79. PubMed ID: 1064679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. N-trifluoroacetyladriamycin-14-valerate, an analog with greater experimental antitumor activity and less toxicity than adriamycin.
    Israel M; Modest EJ; Frei E
    Cancer Res; 1975 May; 35(5):1365-8. PubMed ID: 1054622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNA breaks in P288 tumor cells in mice after treatment with daunorubicin and adriamycin.
    Schwartz HS
    Res Commun Chem Pathol Pharmacol; 1975 Jan; 10(1):51-64. PubMed ID: 1124321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA topoisomerase II-mediated interaction of doxorubicin and daunorubicin congeners with DNA.
    Bodley A; Liu LF; Israel M; Seshadri R; Koseki Y; Giuliani FC; Kirschenbaum S; Silber R; Potmesil M
    Cancer Res; 1989 Nov; 49(21):5969-78. PubMed ID: 2551497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical activity of detorubicin: a new anthracycline derivative.
    Jacquillat C; Auclerc MF; Weil M; Maral J; Degos L; Auclerc G; Tobelem G; Schaison G; Bernard J
    Cancer Treat Rep; 1979 May; 63(5):889-93. PubMed ID: 455330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cellular pharmacology of N,N-dimethyl daunorubicin and N,N-dimethyl adriamycin.
    Egorin MJ; Clawson RE; Ross LA; Bachur NR
    Cancer Res; 1980 Jun; 40(6):1928-33. PubMed ID: 7371027
    [No Abstract]   [Full Text] [Related]  

  • 14. Role of host defense merchanisms in the antitumor activity of adriamycin and daunomycin in mice.
    Mantovani A; Polentarutti N; Luini W; Peri G; Spreafico F
    J Natl Cancer Inst; 1979 Jul; 63(1):61-6. PubMed ID: 286835
    [No Abstract]   [Full Text] [Related]  

  • 15. Distribution and antitumor activity of adriamycin given in a high-dose and a repeated low-dose schedule to mice.
    Pacciarini MA; Barbieri B; Colombo T; Broggini M; Garattini S; Donelli MG
    Cancer Treat Rep; 1978 May; 62(5):791-800. PubMed ID: 657163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ["Chimeric" antibiotics, daunorubicin and its analogs N-acylated with bruneomycin (Streptonigrin)].
    Tolstikov VV; Kozlova NV; Iartseva IV; Preobrazhenskaia MN
    Bioorg Khim; 1989 Feb; 15(2):277-80. PubMed ID: 2500939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Electron microscopic studies of the heart and light microscopic studies of the skin after treatment of golden hamsters with adriamycin, detorubicin, AD-32, and aclacinomycin.
    Dantchev D; Slioussartchouk V; Paintrand M; Hayat M; Bourut C; Mathé G
    Cancer Treat Rep; 1979 May; 63(5):875-88. PubMed ID: 455329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Experimental and clinical activity of a new anthracycline derivative: detorubicin (14-diethoxyacetoxydaunorubicin).
    Maral R; Heusse D; Lavelle F; Cueille G; Marlard M; Jacquillat C; Maral J; Auclerc MF; Weil M; Auclerc G; Bernard J
    Recent Results Cancer Res; 1980; 74():172-83. PubMed ID: 7444138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity of anthracyclines against an adriamycin (NSC-123127)-resistant subline of P388 leukemia with special emphasis on cinerubin A (NSC-18334).
    Johnson RK; Ovejera AA; Goldin A
    Cancer Treat Rep; 1976 Jan; 60(1):99-102. PubMed ID: 826316
    [No Abstract]   [Full Text] [Related]  

  • 20. Alterations in adriamycin efficacy by phenobarbital.
    Reich SD; Bachur NR
    Cancer Res; 1976 Oct; 36(10):3803-6. PubMed ID: 954004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.